Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection (Q36361254)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

0 references

2

object named as

G Kaplan

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

author name string

H Teppler

1

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

K A Smith

3

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

A L Montana

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

P Meyn

5

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Z A Cohn

6

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

0 references

publication date

1 February 1993

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Journal of Experimental Medicine

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

177

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

483-492

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Treatment of immunodeficiency with interleukin-2: initial exploration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Systemic administration of interleukin-2 in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Interleukin-2: inception, impact, and implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Mechanisms of T-cell functional deficiency in the acquired immunodeficiency syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Projections of AIDS morbidity and mortality in San Francisco

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Cutaneous response to recombinant interleukin 2 in human immunodeficiency virus 1-seropositive individuals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Interleukin-2 toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Therapy of acquired immune deficiency syndrome with recombinant interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

30 September 2017

Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

28 June 2018

Plasma viremia in human immunodeficiency virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

28 June 2018

Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

28 June 2018

Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

22 September 2018

Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2190894

22 September 2018

Defective T-cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/8093894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of interleukin-2 in patients with acquired immunodeficiency syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/8093894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/8093894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition

1 reference

https://pubmed.ncbi.nlm.nih.gov/8093894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/8093894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/8093894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/8093894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1084/JEM.177.2.483

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36361254&oldid=1627847939"